{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:37Z","timestamp":1791497917492,"version":"4.3.4"},"reference-count":58,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite the rapid development of efficient and safe vaccines against COVID-19, the need to confine the pandemic and treat infected individuals on an outpatient basis has led to the approval of oral antiviral agents. Taking into account the viral kinetic pattern of SARS-CoV-2, it is of high importance to intervene at the early stages of the disease. A protease inhibitor called nirmatrelvir coupled with ritonavir (NMV\/r), which acts as a CYP3A inhibitor, delivered as an oral formulation, has shown much promise in preventing disease progression in high-risk patients with no need for supplemental oxygen administration. Real-world data seem to confirm the drug combination\u2019s efficacy and safety against all viral variants of concern in adult populations. Although, not fully clarified, viral rebound and recurrence of COVID-19 symptoms have been described following treatment; however, more data on potential resistance issues concerning the Mpro gene, which acts as the drug\u2019s therapeutic target, are needed. NMV\/r has been a gamechanger in the fight against the pandemic by preventing hospitalizations and halting disease severity; therefore, more research on future development and greater awareness on its use are warranted.<\/jats:p>","DOI":"10.3390\/v14112540","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:26:04Z","timestamp":1668655564000},"page":"2540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir\/Ritonavir"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Medical School, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-1865","authenticated-orcid":false,"given":"Georgios","family":"Schinas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical School, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Gogos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical School, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"Parasher","year":"2021","journal-title":"Postgrad Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1038\/s41598-021-84781-x","article-title":"Individualized prediction of COVID-19 adverse outcomes with MLHO","volume":"11","author":"Estiri","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e210830","DOI":"10.1001\/jamanetworkopen.2021.0830","article-title":"Sequelae in Adults at 6 Months After COVID-19 Infection","volume":"4","author":"Logue","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_4","unstructured":"NIH (2022, November 01). COVID-19 Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management-of-adults\/nonhospitalized-adults--therapeutic-management\/."},{"key":"ref_5","unstructured":"European Centre for Disease Prevention and Control 2022 (2022, November 05). High-Risk Groups for COVID-19. Available online: www.ecdc.europa.eu\/en\/covid-19\/high-risk-groups."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/13696998.2021.1886109","article-title":"Health outcomes and economic burden of hospitalized COVID-19 patients in the United States","volume":"24","author":"Shea","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-020-02278-5","article-title":"How the pandemic might play out in 2021 and beyond","volume":"584","author":"Scudellari","year":"2020","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sallam, M. (2021). COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines, 9.","DOI":"10.1101\/2020.12.28.20248950"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 Breakthrough Infections in Vaccinated Health Care Workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJMc2107717","article-title":"Effect of Vaccination on Household Transmission of SARS-CoV-2 in England","volume":"385","author":"Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13063-021-05134-7","article-title":"Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): Study protocol for a cluster-randomized trial","volume":"22","author":"Tan","year":"2021","journal-title":"Trials"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"o1695","DOI":"10.1136\/bmj.o1695","article-title":"COVID-19: FDA authorises pharmacists to prescribe Paxlovid","volume":"378","author":"Tanne","year":"2022","journal-title":"BMJ"},{"key":"ref_16","unstructured":"EMA (2022, November 05). COVID-19 Treatments. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-treatments."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eabc7112","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response","volume":"6","author":"Goyal","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40121-020-00349-8","article-title":"Early Treatment of COVID-19 Disease: A Missed Opportunity","volume":"9","author":"Forrest","year":"2020","journal-title":"Infect Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/psp4.12543","article-title":"Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load","volume":"9","author":"Bertrand","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s10389-021-01478-1","article-title":"Incubation period for COVID-19: A systematic review and meta-analysis","volume":"30","author":"Rai","year":"2022","journal-title":"Z Gesundh. Wiss."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMe2202160","article-title":"The Potential of Intentional Drug Development","volume":"386","author":"Rubin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., and Ziebuhr, J. (2005). Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol., 3.","DOI":"10.1371\/journal.pbio.0030428"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Razali, R., Asis, H., and Budiman, C. (2021). Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms, 9.","DOI":"10.3390\/microorganisms9122481"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ahmad, B., Batool, M., Ain, Q.U., Kim, M.S., and Choi, S. (2021). Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179124"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/375233","article-title":"A review of low-dose ritonavir in protease inhibitor combination therapy","volume":"36","author":"Cooper","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","unstructured":"(2022, November 03). PAXLOVID SPC. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jama.2022.0335","article-title":"COVID-19 Therapeutics for Nonhospitalized Patients","volume":"327","author":"Gandhi","year":"2022","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Baden, L., Cheng, V.C.C., Edwards, K.M., Gallagher, J.C., Gandhi, R.T., Muller, W.J., and Nakamura, M.M. (2022). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis., ciac724.","DOI":"10.1093\/cid\/ciac724"},{"key":"ref_34","first-page":"m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_36","unstructured":"Najjar-Debbiny, R., Gronich, N., Weber, G., Khoury, J., Amar, M., Stein, N., Goldstein, L.H., and Saliba, W. (2022). Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin. Infect. Dis., ciac443."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wong, C.K.H., Au, I.C.H., Lau, K.T.K., Lau, E.H.Y., Cowling, B.J., and Leung, G.M. (2022). Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: A retrospective cohort study. Lancet Infect. Dis.","DOI":"10.1101\/2022.05.19.22275291"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","article-title":"Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Yip, T.C.F., Lui, G.C.Y., Lai, M.S.M., Wong, V.W.S., Tse, Y.K., Ma, B.H.M., Hui, E., Leung, M.K.W., Chan, H.L.Y., and Hui, D.S.C. (2022). Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. Clin. Infect. Dis., ciac687.","DOI":"10.2139\/ssrn.4112160"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dryden-Peterson, S., Kim, A., Kim, A.Y., Caniglia, E.C., Lennes, I., Patel, R., Gainer, L., Dutton, L., Donahue, E., and Gandhi, R.T. (2022). Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. medRxiv.","DOI":"10.1101\/2022.06.14.22276393"},{"key":"ref_41","unstructured":"Ganatra, S., Dani, S.S., Ahmad, J., Kumar, A., Shah, J., Abraham, G.M., McQuillen, D.P., Wachter, R.M., and E Sax, P. (2022). Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19. Clin. Infect. Dis., ciac673."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"830","DOI":"10.15585\/mmwr.mm7125e2","article-title":"Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment\u2014California, December 2021-May 2022","volume":"71","author":"Malden","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_43","unstructured":"Allen, S., Jonhson, K., Haddock, J., Trinkl, J., Nariani, S., and Joyce, B. (2022, November 01). Game Changer: Paxlovid Reduces Hospitalizations and Saves Lives. Cosmos Study. Available online: https:\/\/epicresearch.org\/articles\/game-changer-paxlovid-reduces-hospitalizations-and-saves-lives."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lewnard, J.A., Malden, D., Hong, V., Puzniak, L., Kim, J.S., Shaw, S.F., Takhar, H., Jodar, L., McLaughlin, J.M., and Tartof, S.Y. (2022). Effectiveness of nirmatrelvir-ritonavir against hospital admission: A matched cohort study in a large US healthcare system. medRxiv.","DOI":"10.1101\/2022.10.02.22280623"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wai, A.K.-C., Chan, C.Y., Cheung, A.W.-L., Wang, K., Chan, S.C.-L., Lee, T.T.-L., Luk, L.Y.-F., Yip, E.T.-F., Ho, J.W.-K., and Tsui, O.W.-K. (2022). Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg. Health West Pac., 100602.","DOI":"10.1016\/j.lanwpc.2022.100602"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gentile, I., Scotto, R., Moriello, N.S., Pinchera, B., Villari, R., Trucillo, E., Ametrano, L., Fusco, L., Castaldo, G., and Buonomo, A.R. (2022). Nirmatrelvir\/Ritonavir and Molnupiravir in the Treatment of Mild\/Moderate COVID-19: Results of a Real-Life Study. Vaccines, 10.","DOI":"10.1101\/2022.08.23.22278585"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/AOG.0000000000004900","article-title":"Short-term Pregnancy Outcomes After Nirmatrelvir\u2013Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)","volume":"140","author":"Loza","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Qian, G., Wang, X., Patel, N.J., Kawano, Y., Fu, X., Cook, C.E., Vanni, K.M.M., Kowalski, E.N., Banasiak, E.P., and Banasiak, E.P. (2022). Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study. medRxiv.","DOI":"10.1101\/2022.10.27.22281629"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ranganath, N., O\u2019Horo, J.C., Challener, D.W., Tulledge-Scheitel, S.M., Pike, M.L., O\u2019Brien, R.M., Razonable, R.R., and Shah, A. (2022). Rebound Phenomenon after Nirmatrelvir\/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons. Clin. Infect. Dis., ciac481.","DOI":"10.1093\/cid\/ciac481"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Epling, B.P., Rocco, J.M., Boswell, K.L., Laidlaw, E., Galindo, F., Kellogg, A., Das, S., Roder, A., Ghedin, E., and Kreitman, A. (2022). Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir\/Ritonavir Treatment. Clin. Infect. Dis., ciac663.","DOI":"10.1093\/cid\/ciac663"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Truong, T.T., Ryutov, A., Pandey, U., Yee, R., Goldberg, L., Bhojwani, D., Aguayo-Hiraldo, P., Pinsky, B.A., Pekosz, A., and Shen, L. (2021). Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv.","DOI":"10.1101\/2021.02.27.21252099"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Motyan, J.A., Mahdi, M., Hoffka, G., and Tozser, J. (2022). Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073507"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2241434","DOI":"10.1001\/jamanetworkopen.2022.41434","article-title":"Early Adoption of Anti\u2013SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022","volume":"5","author":"Bajema","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy","volume":"222","author":"Helleberg","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_55","unstructured":"(2022, November 01). ClinicalTrials.gov. (2022). NCT, Available online: www.clinicaltrials.gov\/ct2\/show\/NCT05047601."},{"key":"ref_56","unstructured":"(2022, November 01). ClinicalTrials.gov. (2022). NCT, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05011513."},{"key":"ref_57","unstructured":"(2022, November 01). ClinicalTrials.gov. (2022). NCT, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05438602."},{"key":"ref_58","unstructured":"(2022, November 01). ClinicalTrials.gov. (2022). NCT, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05261139."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:20:00Z","timestamp":1760145600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112540"],"URL":"https:\/\/doi.org\/10.3390\/v14112540","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}